06.03.2023 • News

Clean Cells Opens New €22 Million Facility

Clean Cells, part of France’s Clean Biologics group, which provides biopharmaceutical product quality control services and manufactures starting materials, has begun analytical activities at its new €22 million facility in Montaigu-Vendée, near Nantes.

With an area of 5,300m2, the company said the new site offers four times more laboratory space than the previous building and represents a “major milestone” in its development. A new state-of-the-art monitoring system is expected to provide better pharmaceutical organization.

The aim of the revamp is to enable the company to develop its activities in innovative sectors such as gene therapy, with the implementation of new tests to meet the needs of the market. Going forward, Clean Cells said it will be able to offer new and improved innovative platforms, including next-generation sequencing (NGS) and karyotyping.

Joseph Jammal, CEO of the Clean Biologics group, said the project represents the culmination of five years of planning, design and construction to support the subsidiary’s growth in response to market demands.

© Clean Cells
© Clean Cells

Especially in viral safety and genetic stability, the lab space offers much greater potential for strong growth, the group believes. Testing capacities have been increased fourfold, and cell bank production capacity has doubled, allowing the development of biopharmaceutical drugs to be accelerated.  

Clean Cells plans to recruit 20 new staff in 2023. It currently employs 130 people.

Gwenaël Autret, head of quality control, said the new laboratories will allow a significant increase in biosafety testing, and cytogenetic and potency assay capacities.

The global biologics safety testing market was estimated to be worth $3.6 billion in 2022 and should reach $6.8 billion in 2027, the company said. This represents a CAGR of 13.3%, driven by the expanding development of biologics and biosimilars, growing concerns over cell culture contamination and rising biopharmaceutical R&D investment.

Author: Dede Williams, Freelance Journalist

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

March 24, 2026 | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.